• Adaptate Biotherapeutics Raises $18 million

Adaptate Biotherapeutics Raises $18 million in Series A2 Funding

19th April, 2021|

Adaptate Biotherapeutics Raises $18 million in Series A2 Funding Investment will accelerate the progression of the Company’s lead therapeutic antibody programme towards the clinic and further expand its internal product pipeline Latest financing takes [...]

  • adaptate

Iontas & Adaptate Collaborate

3rd December, 2019|

IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets Cambridge, UK, 03 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has [...]

  • adaptate

Adaptate Formed

16th October, 2019|

Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells GammaDelta Therapeutics spins-out new company to accelerate antibody-based assets towards clinical studies London, UK, 16th October 2019: GammaDelta Therapeutics, a company focussed on [...]

Talk to US

This form collects your name and email to enable us to contact you regarding your enquiry. For further information on how we protect and manage your submitted data view our privacy policy.

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.